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ABSTRACT
Background: Gonadotropins, as ovulation-inducing drugs, have been used
widely to treat infertility. An epidemiologic correlation between infertility ther-
apy and ovarian cancer development has been reported. However, the effect of
gonadotropins in the formation of reproductive tract cancers is controversial.
Objective: The aim of the study was to determine the in vivo genotoxic effects
of gonadotropins on rat reticulocytes.
Methods: In this prospective, randomized, controlled study, rats were
andomly assigned to 1 of 5 groups. The calculated rat doses of 0.65 human
enopausal gonadotropin (hMG), 0.95 hMG, 0.65 follitropin beta (FB), 0.95 FB,
r normal saline (control group) were injected, respectively. These calculated rat
oses (U/g) are based on average human gonadotropin doses of 150 and 225 IU/d
or a 70-kg woman given in 2-mL saline (the control group received 2 mL of
aline). Injections were administered once per day for 5 days, followed by 5 days
f rest. Each treatment was repeated for 6 estrus cycles in the rats for a total of
2 estrus cycles. Six months after the last day of the 12th cycle, the rats were
euthanized. Bone marrow tissues were removed, and pluripotent reticulocyte cells
with micronuclei, nuclear buds, and binuclear abnormalities were analyzed using
an in situ micronuclei assay under light microscopy. The proportion of micro-
nucleated cells, cells with anaphase bridge, nuclear buds, and other nuclear
abnormalities were measured.
Results: The number of cells with nuclear buds and binuclear abnormalities in
the hMG 225 and FB 225 groups was significantly higher (P  0.05) than that from
the hMG 150, FB 150, and control groups in the cytogenetic analysis of bone marrow
stem cells. An increased rate of genotoxicity in all gonadotropin groups versus that
of placebo was found.
Conclusion: In rats, the micronucleus genotoxicity assay suggests a dose-
ependent gonadotropin effect on genomic instability in bone marrow stem cells in
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INTRODUCTION
Ovulation-inducing drugs have been used widely to treat infertility since the 1960s.
Ovulation induction regimens are the most widespread treatment for ovulation
disorders, which account for approximately 33% of female infertility cases.1 Clomi-
phene citrate (CC), bromocriptine, gonadotropins, and gonadotropin-releasing hor-
mone analogs are the treatment options for infertile women.2 An epidemiologic
correlation between infertility therapy and ovarian cancer development has been
reported3; in particular, human menopausal gonadotropin (hMG) was reported to
ncrease the risk of developing epithelial ovarian tumors4; hence, the possible role of
onadotropins in ovarian carcinogenesis has received much attention. The effect of
onadotropins on epithelial ovarian carcinoma by stimulating cell proliferation and/or
nhibiting apoptosis in ovarian surface epithelium is advocated for the histogenetic
rigin of carcinomas.5,6 These data suggest that gonadotropins play an important role
n the development, progression, and chemoresistance of ovarian carcinomas.5,6
Although several recent studies have proposed a connection between fertility drugs
and ovarian cancer,7–9 no strong association has been firmly established as addressed
n some reports.10–12
Micronuclei are pieces of extranuclear chromatin that originate when chromosome
fragments or lagging whole chromosomes fail to be incorporated into daughter nuclei
as cells divide. The occurrence of micronuclei increases following the exposure to
clastogenic agents that cause double-strand DNA breaks and to aneugens that
discontinue chromosomal segregation.13,14 The in vivo rodent micronucleus (MN)
est is used widely to identify or study chemicals with genotoxic potential.15–17
Numerous studies have reported on the incessant ovulation hypothesis18 and oxida-
ive damage products in ovarian surface epithelium DNA as contributors to the risk
f developing cancer.19–21 The genotoxic potential of ovulation and genomic integ-
ity of the ovarian surface epithelium have been investigated.22 However, no research
was carried out to explore the genototoxic effects of gonadotropins on rodent MN.
The purpose of this study is to evaluate the genotoxic effects of gonadotropins on
rat reticulocytes in situ MN assay.
MATERIALS AND METHODS
This study was conducted at Abant Izzet Baysal University (AIBU), Faculty of
Medicine, between March 2008 and January 2009. The Committee of Animal Care
and Use at AIBU approved the procedures, which are in line with the Declaration of
Helsinki and the Guiding Principles in the Care and Use of Animals. The rats were
kept in the laboratory for at least 4 weeks before the experiments. A total of 40
sexually mature, nontransgenic female Wistar albino rats (body weight, 220–250 g)
at 20 weeks of age were assigned to 1 of 5 groups: 0.65 IU intramuscular hMG
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MH] group [n  8]); 0.65 IU subcutaneous follitropin beta (recombinant low [RL]
roup [n 8]); 0.95 IU subcutaneous follitropin beta (recombinant high [RH] group
n  8]); and control rats (saline group [n  8]). Follitropin beta (Puregon) was
provided by Organon Laboratories Limited (Cambridge, United Kingdom) and
menogon was provided by Ferring Pharmaceuticals (Copenhagen, Denmark).
These calculated rat doses (units/gram) were based on average human gonadotropin
doses of 150 to 225 IU/d for a 70-kg woman and were given in 2-mL saline for
infertility; control rats received only 2 mL of subcutaneous saline.
Before the study, the estrus cycle was confirmed by vaginal cytology, and only
rats with an estrus cycle of 5 days were included.23 The rats were injected for 5
ays once daily, beginning on the first estrus cycle day, which was followed by 5
ays of rest (an unmedicated cycle) during 1 course of therapy; 6 cycles of
onadotropins were given in a total of 12 estrus cycles. All the animals were bred,
ed, and watered ad libitum under standard laboratory conditions in separate
ages for 6 months after the last day of the 12th cycle until the euthanization by
cervical dislocation.
Micronuclei Analysis
Different researchers blind to the treatment groups assessed the results and
evaluated an equal number of slides from unmarked slide boxes that the groups were
allocated during the study. Bone marrow was prepared according to the method
described by D’Souza et al24 and Schmid.14 First the femurs were removed from each
animal; bone marrow stem cells from the control and experimental groups were
removed using a thin brush. The MN assay was completed as recommended by
standard procedures25–29 with some modifications appropriate for in situ evalua-
tion.29,30 Briefly, after a few deep strokes into the stem cell tissue with a brush, the
cells were spread on clean slides, which were then coded. After the last superficial
stroke had been diluted with Hank’s balanced salt solution, spread slides were
prepared. Four slides were prepared for each group. After the stem cells in the
control and experimental groups were stained with 5% Giemsa dye in Sorensen’s
buffer (pH 6.8), the slides were rinsed twice with fresh Sorensen’s buffer and air
dried. Subsequently, MN frequencies were scored in the youngest fraction of
reticulocytes. The immature polychromatic erythrocytes were validated from
mature normochromatic erythrocytes cells and evaluated as an in vivo rat model
assay. The proportion of micronucleated erythrocytes and cells with other fea-
tures—mononucleated, binucleated, anaphase bridges, or nuclear buds—were
counted in 1000 cells per slide using a lighted microscope (Zeiss Axioskop 2 plus;
Carl Zeiss MicroImaging, Thornwood, New York) equipped with a 100 im-
mersion objective (final magnification: 1000) and a charge-coupled device
camera. The polychromatic erythrocyte cells were scored by a cytogeneticist to
determine the percentages of micronucleated cells, and to compare the control
group rats in the current observer-blinded study.
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B. Duran et al.Statistical Analysis
Statistical analysis was performed using the Statistical Package for Social Sciences
11.5 software (SPSS Inc., Chicago, Illinois). The distributional properties of metric
discrete variables were determined with the Shapiro Wilk test. Nonparametric data
were expressed as median (minimum–maximum range), and the differences among
groups were evaluated by using the Kruskal-Wallis test. When the P value from
ruskal-Wallis test statistics was found to be statistically significant, group differ-
nces were identified by nonparametric multiple comparison tests. P  0.05 was
onsidered statistically significant.
RESULTS
The distribution of nuclear abnormalities in the ML, MH, RL, RH, and control
groups are presented in the Table. No cells with attached MN, binucleated cells with
N, cells with anaphase bridges, or cells with nuclear buds were observed in the
ontrol group. Apart from the control group, varying degrees of nuclear abnormalities
ere detected in the ML, MH, RL, and RH groups.
The mean (minimum–maximum range) of mononuclear cells in the ML (145
120–180]) and RL (60 [50–80]) groups was significantly lower than that of the
ontrol group (235 [180–345]); P  0.021 and P  0.001, respectively (Table).
ore abnormalities for cells with attached MN were found in ML (10 [5–14]), MH
34 [20–50]), RL(10 [6–14]), and RH (8 [2–20]) groups compared with the control
roup (0 [0–1]), P  0.05. However, the number of cells with attached MN in RL
nd RH groups was significantly lower than that in the MH group (P  0.01). The
number of binucleated cells with MN in ML (1 [0–3]), MH (3 [1–6]), and RH (2
[0–6]) groups was significantly higher than that of the control group (0 [0–1]); P 
0.029 for ML versus control, and P  0.001 for MH and RH versus control,
respectively. The number of binucleated cells with MN in the MH group was
significantly higher than that in both the ML and RL groups (1 [0–1]); P  0.006
nd P  0.01, respectively. Moreover, the number of cells with nuclear bud abnor-
alities was higher in ML (2 [0–4]), MH (1 [0–4]), RL (1 [0–2]), and RH (4 [2–6])
roups than in the control group (0 [0–1]); P  0.012, P  0.004, P  0.031, and
 0.001, respectively. The nuclear bud abnormalities were the highest in the RH
roup and were significantly higher than the ML, MH, and RL groups; P  0.002,
 0.007, and P  0.001, respectively.
Furthermore, no significant changes in the number of cells with anaphase bridges
ere noted in any of the groups. Some abnormal bone marrow cell profiles (cells with
uclear buds, cells with micronuclei, cells with anaphase bridge abnormality) of the
xperimental group of rats are depicted in the Figure.
DISCUSSION
Exposure to different substances in daily life requires an alternative technique for
monitoring personal gene damage. The evaluation of the genotoxic safety of drugs and
other chemical agents is an extremely important aspect of toxicologic work in
biological systems. The combined use of chemical analysis techniques (biomonitoring
63
Table. Distribution of nuclear abnormalities in reticulocyte cells in experimental (ML, MH, RL, and RH) and control groups.
Cell Feature
Group
Control ML MH RL RH
Mean
(min–max)
Mean
(min–max)
Mean
(min–max)
Mean
(min–max)
Mean
(min–max)
Mononuclear cell 235 (180–345) 145 (120–180)* 323 (120–450)† 60 (50–80)*†‡ 183 (90–375)§
Cell with BN 2 (0–3) 15 (8–22)* 24 (18–35)*† 7 (3–10)*†‡ 15 (4–35)*§
Cell with attached MN 0 (0–1) 10 (5–14)* 34 (20–50)*† 10 (6–14)*‡ 8 (2–20)*‡
Binucleated cell with MN 0 (0–1) 1 (0–3)* 3 (1–6)*† 1 (0–1)‡ 2 (0–6)*
Cell with AB 0 (0–0) 1 (0–2) 1 (0–5) 0 (0–2) 1 (0–2)
Cell with NB 0 (0–1) 2 (0–4)* 1 (0–4)* 1 (0–2)* 4 (2–6)*†‡§
AB  anaphase bridge; BN  binucleated cell; MH  menogon high; ML  menogon low; MN  micronucleus; NB  nuclear bud; RH  recombinant
high; RL  recombinant low.
*P  0.05 vs control.
†P  0.05 vs ML.
‡P  0.01 vs MH.
§P  0.05 vs RL.
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B. Duran et al.assay) plays a crucial role in the identification of specific toxic and mutagenic damage
caused by some environmental agents in the biological systems. In addition to
biological samples such as blood, urine, and cerebrospinal fluid, bone marrow and
solid tissues are used to evaluate the genotoxic and cytotoxic effects of agents. Because
bone marrow is one of the incessantly proliferating tissues in adult animals, it has
been preferred as a common target organ for cytogenetic studies. One of the most
promising methods at present is the in situ MN assay that detects large chromosomal
breakages in the early human biomonitoring system.15–17 The rat bone marrow MN
assay is a standard in vivo genotoxicity test that has been performed widely to assess
the clastogenic potential of chemicals.15–17 In the present study, a direct in situ MN
ssay technique was used to explore gonadotropin genotoxicity in a rat model. CC and
onadotropins are the most commonly used ovulation-inducing agents.31–33
The available data on the possible relationship between these agents and ovarian
cancer are inconclusive, although theoretical considerations and clinical observations
suggest such a relationship is likely. In addition, the association with fertility drugs,
especially between gonadotropins and ovarian cancer, is supported by case reports and
epidemiologic studies.3,4,34–36 Research37,38 supports the pituitary gonadotropin
hypothesis39 and mutagenic potential of gonadotropins. For example, Mertens-
Figure. Some abnormal bone marrow cell profiles of experimental group rats. Arrows show
the abnormal structures. A: Cell with nuclear bud; B and E: Cells with nuclear buds
that derivated from anaphase bridge abnormalities; C, D and F: Cells with micro-
nuclei; G: Cell with anaphase bridge abnormality; H: Normal cell.Walker et al37 suggested that gonadotropins induce both ovarian cancer cell migra-
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Current Therapeutic Researchtion and proliferation by activation of extracellular signal-regulated kinase 1/2
signaling in a calcium-dependent and protein kinase C delta-dependent manner. A
recent article reported use of cDNA microarray analysis on MCV152 cells with
gonadotropin treatment, which revealed that gonadotropins promoted cell growth in
ovarian surface epithelial cell lines.38 Discordant with these reports, Ness et al40
found no association between fertility drug use and the overall risk of ovarian cancer
and concluded that neither duration nor unsuccessful use of fertility drugs was related
to adjusted cancer risk. To the best of our knowledge, no experimental studies have
investigated the genotoxic or cytotoxic effects of gonadotropins in rat in situ MN
assay. In vivo erythrocyte MN assays in biological systems are extensively used to
evaluate the potential genotoxic and cytotoxic effects of chemical and physical agents.
Scoring of micronuclei has been proposed as an alternative to conventional chromo-
some aberrations analysis, because it is more sensitive and faster in eukaryotic cell
transformation and tumorigenesis.31,41,42 These assays are effective in detecting MN
ormation in target cell/tissue DNA material and indicate the genotoxicity and
utagenicity of such chemicals in biological systems.43 Almost all agents that cause
double-strand chromosome breaks (clastogens) induce micronuclei.13,14 The induc-
tion of DNA damage and chromosomal breakages due to mutations is the primary
mechanism by which cancers arises. In a previous study, no statistically significant
difference was found between the CC and the control groups in terms of anaphase
bridges and MN formation, which are strong indicators of genotoxicity.30 However,
statistically significant differences were observed between the CC and the control
groups for nuclear buds and binuclear cells, which are weak indicators of genotoxicity.
The results indicated that CC has a dose-dependent mutagenic effect on the nuclear
genome of pluripotent stem cells in rats.30
In the current study, statistically significant differences were detected among all
parameters of cell abnormalities and MN cells except for the anaphase bridge
abnormality by using high doses of subcutaneous gonadotropins. Moreover, signifi-
cant differences were seen in the high-dose hMG compared with low-dose hMG and
control groups in term of cells with binucleated cells, cells with attached MN, and
binucleated cells with MN. A statistically significant increase was monitored in the
number of cells with nuclear buds and cells with MN in the high-dose follitropin beta
group when compared with the low dose and control group rats.
The current results provide in vivo data from a rat model and suggest possible
mutagenic effects of gonadotropins on rat reticulocytes. Results further suggest that
the in situ evaluation of rat pluripotent stem cells in vivo works well as a method for
accurately determining the genotoxic effects of gonadotropins. The validation efforts
are based on the key role of in vivo rat MN testing in pharmaceutical safety assays,
and mutagen sensitivity detected with the MN testing are also reported in various
articles.26–29,44 It is likely that hyperproliferative rat bone marrow stem cells are
mong the most sensitive targets for drugs such as gonadotropins and CC.30 Based on
he presented results here, it can be concluded that in vivo gonadotropin exposure
erves as an important parameter for genomic instability in rat proliferative stem cells.
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B. Duran et al.Furthermore, Chene et al8 identified a relationship between ovarian epithelial
ysplasia and ovulation-inducing drugs; Fathalla18 described an incessant ovulation
theory as well as the dose and the time effect of ovarian stimulation, which may be
the possible explanation of this dysplasia.18 In addition to dysplasia, peripheral blood
lymphocytes exhibit DNA damage in most cases of cancer. The measurement of MN
in peripheral blood lymphocytes is frequently used in molecular epidemiology as one
of the preferred methods of assessing sporadic chromosomal damage resulting from
environmental mutagen exposure; however, the current study puts forward the
genetic evaluation of bone marrow reticulocytes.The MN assay has also been used to
assess DNA damage before and after exposure to iodine-131 in thyroid cancer cases.45
Results suggested that image analysis of MN can be used as a highly sensitive method
of evaluating the effect of long-term gonadotropin use. In addition, it is observed that
ovulation-inducing drugs are able to increase MN frequency in rat reticulocyte cells
in vivo. The current method is acceptable for biomonitoring studies46,47 focusing on
he measurement of MN in assessing chromosomal damages as a result of environ-
ental mutagens or medical applications.
The limitation of the current study could be stated as the possible influence of
nterindividual results due to the visual scoring system. An automated scoring system
f slides for quicker and more reliable data acquisition that is not influenced by the
nterindividual and temporal variability of human scorers might enable consistent
esults to be obtained.
CONCLUSION
In conclusion, the data provide evidence that therapy with at least 6 cycles of
gonadotropin could affect overall genomic instability in pluripotent reticulocytes
(proliferative stem cells) and damage their DNA. These findings show increased basal
DNA damage in high-dose gonadotropin-treated rat reticulocytes. Varying degrees of
nuclear abnormalities were detected in ML, MH, RL, and RH groups compared with
those in the control group. The study might play a precursor role for future human
studies that will be performed using cytogenetic methods on MN, evaluating geno-
toxic effects of gonadotropin use for infertility treatment.
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